EXPLORE THE SCIENCE
TL;DR: A 2026 secondary analysis in Addiction found that adults switched to very-low-nicotine cigarettes often used alternative nicotine products and maintained much higher nicotine intake than cigarette-only users. Key Findings 438 smokers: The parent randomi…
Read article
TL;DR: A 2026 systematic review in Preventive Medicine Reports found limited but suggestive randomized-trial evidence that smoking-cessation medications can help Indigenous adults quit, especially when paired with supportive or culturally tailored care. Key Fi…
Read article
TL;DR: A 2026 randomized clinical trial in JAMA Network Open found that one supervised 30 mg/70 kg psilocybin dose plus cognitive behavioral therapy produced 40.5% six-month smoking abstinence versus 10.0% with a nicotine patch plus the same therapy. Key Findi…
Read article
TL;DR: A 2026 medRxiv preprint found that ex-smokers had higher fMRI blood oxygen level dependent (BOLD) responses to high-energy food pictures than adults with obesity or abstinent alcohol dependence, suggesting a brain reward route for post-quitting weight g…
Read article
New research provides clarity on the most effective cessation aids available. Varenicline, cytisine, and e-cigarettes help the greatest proportion of people quit long-term. Slowly tapering nicotine dose before ending treatment may also boost success rates. Bup…
Read article
Antidepressant medications like bupropion (Zyban) show potential to help people quit smoking long-term. However, the evidence is complex with both benefits and risks to consider carefully. Key facts: The antidepressant bupropion (brand name Zyban) aids quittin…
Read article